ERBB2 oncogene in human breast cancer and its clinical significance
- 1 May 1998
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 34 (6), 791-808
- https://doi.org/10.1016/s0959-8049(97)10157-5
Abstract
No abstract availableKeywords
This publication has 130 references indexed in Scilit:
- Plasma c-erbB2 concentrations in relation to chemotherapy in breast cancer patientsEuropean Journal Of Cancer, 1996
- c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancerEuropean Journal Of Cancer, 1995
- Cellular accumulation of p53 protein: an independent prognostic factor in stage II breast cancerEuropean Journal Of Cancer, 1994
- Coexpression of HER-2/neu and p53 is associated with a shorter disease-free survival in node-positive breast cancer patientsZeitschrift für Krebsforschung und Klinische Onkologie, 1994
- Determination of a fragment of the c-erbB-2 translational product p185 in serum of breast cancer patientsZeitschrift für Krebsforschung und Klinische Onkologie, 1993
- Co-amplification of erbB2, topoisomerase II α and retinoic acid receptor α genes in breast cancer and allelic loss at topoisomerase I on chromosome 20European Journal Of Cancer, 1993
- Expression of c-erbB2, TGF-β1 and pS2 genes in primary human breast cancersEuropean Journal Of Cancer, 1992
- Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: Correlation with steroid receptorsEuropean Journal Of Cancer, 1992
- Overexpression of the c-erbB-2 oncoprotein: Why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance?European Journal Of Cancer, 1992
- Epidermal growth factor receptors in breast cancer: Association with early relapse and death, poor response to hormones and interactions with neuJournal of Steroid Biochemistry, 1989